Stocks · Healthcare · Biotechnology
Intellia Therapeutics, Inc. NTLA
$12.26 +1.16% Close, Oct 2, 2026 · NASDAQ · Market cap $1.71B
Expensive vs sector
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to -711.7% from -968.7% a year earlier.
- The diluted share count rose 28.7% in a year.
- The stock is 56% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 43%
- Revenue growth, 3-year CAGRBottom 47%
- Revenue growth accelerationBottom 9%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 23%
- Gross marginBottom 7%
- Operating marginBottom 14%
- Accruals (lower is better)Bottom 48%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 26%
- Free-cash-flow yieldBottom 24%
- EBITDA / enterprise valueBottom 26%
- Sales / enterprise valueBottom 17%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 15%
- 6-month returnBottom 36%
- 1-year return vs S&P 500Bottom 19%
- Distance from 52-week highBottom 20%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 39%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 45%
- Upside to consensus price targetTop 40%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 37%
- Maximum drawdown, 3 yearsBottom 31%
- Beta vs S&P 500 (lower is better)Bottom 13%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 45.0% | 12.6% | ↓ |
| Gross margin | -480.0% | -46.5% | ↑ |
| Operating margin | -968.7% | -711.7% | ↑ |
| FCF margin | -798.0% | -586.0% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 12.6% | 45.0% | ↓ | Top 43% |
| Gross margin | -46.5% | -480.0% | ↑ | Bottom 7% |
| Operating margin | -711.7% | -968.7% | ↑ | Bottom 14% |
| Net margin | -672.2% | -908.5% | ↑ | — |
| Free-cash-flow margin | -586.0% | -798.0% | ↑ | — |
| Return on invested capital | -52.9% | — | Bottom 23% | |
| Revenue growth, 3-year CAGR | 9.1% | — | Bottom 47% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -6.2%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 238.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -48.1 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -20.13%
- Shareholder yield
- -20.13%
- Share count change, 1 year
- +28.7%
- Share count change, 3-year CAGR
- +14.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 7 of 8
- Average EPS surprise, last 4
- +9.5%
- Average 2-day reaction, last 8
- +2.1%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $23.00
- Target vs current price
- +87.6%
- Analysts with a rating
- 39
- Share rating Buy or Strong Buy
- 74%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | -0.1% | +2.5% | +10.2% | +16.3% | — |
| May 11, 2026 | +12.0% | +2.3% | -3.0% | -4.3% | -22.1% |
| Feb 26, 2026 | +16.2% | +6.4% | +3.0% | -1.2% | -7.8% |
| Nov 6, 2025 | +9.8% | -9.2% | -30.1% | -28.2% | -3.8% |
| Aug 7, 2025 | +3.9% | +0.8% | -3.3% | +2.2% | +7.9% |
| May 8, 2025 | +12.7% | +13.6% | +8.1% | +4.0% | +66.3% |
| Feb 27, 2025 | +6.1% | +0.6% | -13.2% | -23.1% | -12.4% |
| Nov 7, 2024 | +2.2% | -0.4% | +0.3% | -15.0% | -34.6% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.80 | -$0.80 | -0.1% | $7.7M |
| May 11, 2026 | -$0.81 | -$0.92 | +12.0% | $15.0M |
| Feb 26, 2026 | -$0.83 | -$0.99 | +16.2% | $23.0M |
| Nov 6, 2025 | -$0.92 | -$1.02 | +9.8% | $13.8M |
| Aug 7, 2025 | -$0.99 | -$1.03 | +3.9% | $14.2M |
| May 8, 2025 | -$1.10 | -$1.26 | +12.7% | $16.6M |
| Feb 27, 2025 | -$1.24 | -$1.32 | +6.1% | $12.9M |
| Nov 7, 2024 | -$1.34 | -$1.37 | +2.2% | $9.1M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 28.24× | — | — | Bottom 17% |
| Free-cash-flow yield | -20.36% | — | — | Bottom 24% |
| Earnings yield | -27.41% | — | — | Bottom 26% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 4
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -7.5%
- 200-day average slope (20 days)
- +2.6%
- Distance from 50-day average
- +2.0%
- Distance from 200-day average
- -4.6%
- RSI (14)
- 51.2
- Relative volume
- 1.02×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 62.5%
- Volatility vs own 5-year history
- 23th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.02
- Correlation with S&P 500
- 0.34
- Current drawdown from 1-year high
- -56.2%
- Maximum drawdown, 3 years
- -80.9%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 3, 2021 | Apr 8, 2025 | -96.5% | 901 days | Not yet recovered |
| Jan 19, 2021 | Mar 8, 2021 | -44.3% | 33 days | 34 days (Apr 26, 2021) |
| Apr 27, 2021 | May 13, 2021 | -30.1% | 12 days | 21 days (Jun 14, 2021) |
| Jul 1, 2021 | Jul 27, 2021 | -22.9% | 17 days | 27 days (Sep 2, 2021) |
| Dec 22, 2020 | Dec 31, 2020 | -14.4% | 6 days | 3 days (Jan 6, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.71B
- EPS, diluted (TTM)
- -$3.36
- Revenue (TTM)
- $59.5M
- 52-week range
- $7.95 – $28.25
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $33.1M | $52.1M | $36.3M | $57.9M | $67.7M |
| Gross profit | $26.2M | $44.5M | $27.3M | $47.6M | $51.7M |
| Operating income | -$267.9M | -$458.2M | -$515.3M | -$534.3M | -$441.0M |
| Net income | -$267.9M | -$474.2M | -$481.2M | -$519.0M | -$412.7M |
| EPS (diluted) | -$3.78 | -$6.16 | -$5.42 | -$5.25 | -$3.81 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.1M | $12.9M | $16.6M | $14.2M | $13.8M | $23.0M | $15.0M | $7.7M |
| Net income | -$135.7M | -$128.9M | -$114.3M | -$101.3M | -$101.3M | -$95.8M | -$96.2M | -$106.6M |
| EPS (diluted) | -$1.34 | -$1.27 | -$1.10 | -$0.98 | -$0.92 | -$0.83 | -$0.81 | -$0.80 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$225.0M | -$333.3M | -$394.1M | -$348.9M | -$348.9M |
| Capital expenditure | -$12.8M | -$58.4M | -$14.0M | -$5.8M | -$5.8M |
| Free cash flow | -$237.8M | -$391.7M | -$408.1M | -$354.7M | -$354.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $693.6M | $565.8M | $119.8M | $176.9M | $131.5M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $437.8M
- Total assets
- $857.2M
- Total liabilities
- $129.5M
- Total debt
- $73.4M
- Net debt
- -$32.7M
- Shareholders’ equity
- $727.7M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 46,681,609
- Days to cover
- 14.10
- Change vs previous report
- +6.3%
FINRA short interest, settlement date Sep 15, 2026.